Month: June 2026

Introduction and Objective: This post hoc analysis assessed efficacy and hypoglycemia outcomes of IcoSema (a once-weekly combination of insulin icodec + semaglutide) vs comparators (COMBINE 1 [C1]: icodec; COMBINE 2 [C2]: semaglutide 1.0 mg; COMBINE 3 [C3]: basal-bolus therapy) in insulin-experienced (C1+3) or GLP-1 RA experienced (C2) adults with T2D by baseline BMI subgroups.Methods: Treatment […]

Introduction and Objective: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated superior glycemic and weight-loss efficacy in randomized trials. However, real-world evidence in South Asian populations remains limited. This study was done to evaluate the early real-world effectiveness and safety of tirzepatide in Indian adults with type 2 […]

Introduction and Objective: Type 1 diabetes (T1D) is an autoimmune disorder marked by islet autoantibodies. First-degree relatives (FDRs) of individuals with T1D have a 10-15-fold higher risk of developing T1D than the general population. Screening for four autoantibodies—glutamic acid decarboxylase (anti-GAD), protein tyrosine phosphatase (anti-IA2), insulin (IAA), and Zinc Transporter 8 (anti-ZnT8)—enables early detection of […]

Introduction and Objective: The literature reports that Mexican American children are at risk for diabetes, hypertension, renal dysfunction, cardiovascular and gallbladder disease, risk increases if the child has overweight or obesity. In 2005 we found that by the age of three 25% of boys and 15% of girls were either overweight or obese, but the […]

Introduction and Objective: Faricimab, the only bispecific antibody targeting both Ang-2 and VEGF-A, is a novel treatment for diabetic macular edema (DME). Real-world evidence is lacking on the impact of baseline diabetes severity on its long-term clinical/economic outcomes.Methods: This retrospective cohort study linked a DME cohort from a large national payer (administrative claims) with the […]

Introduction and Objective: Implementing lifestyle interventions guided by continuous glucose monitor (CGM) data can potentially prevent progression and reduce risk of prediabetes and type 2 diabetes (T2D). Maintaining healthy behaviors is particularly difficult in high-stress work environments like health care workers (HCWs). Sutter Health created a Metabolic Wellness Program (MWP) to educate on interpreting CGM […]

Introduction and Objective: Use of continuous glucose monitoring (CGM) and glucose biosensors are increasing in people without diabetes to support health and wellness. However, there is currently limited data on the CGM profile of older adults without diabetes. This study examined the CGM profile of older men without diabetes over 24 hours.Methods: Thirty-three older men […]

Introduction and Objective: Impaired function of large-conductance Ca²+-activated K+ (BK) channels is associated with coronary artery dysfunction in diabetes mellitus. We previously reported that BK channel function is regulated by Src homology 3 (SH3) domain-containing protein 2 (Sorbs2) and its upstream regulator, nuclear factor erythroid 2-related factor 2 (Nrf2), in the coronary arterial smooth muscle […]

Introduction and Objective: Older adults with obesity are at increased risk for metabolic dysfunction and type 2 diabetes. Aging and excess adiposity promote the accumulation of senescent cells in adipose tissue (AT), contributing to chronic inflammation and impaired adipocyte function. Lifestyle interventions including weight loss and exercise improve metabolic health in older adults with obesity; […]